Lantern Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>LP</div>
The stock is still going through an active upward rally. While some baby boomers are getting worried about healthcare space, it is reasonable to outline Lantern Pharma as an investment alternative. What exactly are Lantern Pharma shareholders getting in September? Here we also measure the ability of Lantern Pharma to meet its long-term debt obligations, such as interest payments on debt, the final principal payment on the debt, and any other fixed obligations like lease payments.
Published over a month ago
View all stories for Lantern Pharma | View All Stories
Does Lantern Pharma (NASDAQ:LTRN) has enough cash to last in September?
The firm currently holds 211.33 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Lantern Pharma has a current ratio of 11.02, suggesting that it is liquid enough and is able to pay its financial obligations when due.

How important is Lantern Pharma's Liquidity

Lantern Pharma financial leverage refers to using borrowed capital as a funding source to finance Lantern Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Lantern Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Lantern Pharma's total debt and its cash.

How Lantern utilizes its cash?

To perform a cash flow analysis of Lantern Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Lantern Pharma is receiving and how much cash it distributes out in a given period. The Lantern Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Lantern Pharma Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (2.3 Million)

Conversion by Green Park Golf Ventures Ii Llc of 75688 shares of Lantern Pharma

Legal trades by Lantern Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Lantern insider trading alert for conversion of series a preferred stock par value $0.01 by Green Park Golf Ventures Ii Llc, the corporate stakeholder, on 17th of June 2020. This event was filed by Lantern Pharma Inc with SEC on 2020-06-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Lantern Pharma Investor Appetite?

Net Loss for the year was (2.66 M).

Asset Breakdown

Assets Non Current
1.1 M
Current Assets
Total Assets1.3 Million
Current Assets1.13 Million
Assets Non Current164,312

Will Lantern Pharma latest rise continue?

The semi variance is down to 19.47 as of today. Lantern Pharma exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Lantern Pharma individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Lantern Pharma future systematic risk.

Our Final Perspective on Lantern Pharma

Whereas few other entities under the biotechnology industry are still a bit expensive, Lantern Pharma may offer a potential longer-term growth to institutional investors. On the whole, as of the 23rd of August 2020, we believe that at this point, Lantern Pharma is somewhat reliable with above average odds of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. However, our present 30 days Buy-Hold-Sell recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Lantern Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com